Soft Tissue Neoplasm of Uncertain Differentiation

subtype

Identifier: CI-CAN-00001532
Entity page: /cancer/soft-tissue-neoplasm-of-uncertain-differentiation ↗
Edges: 317

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Soft Tissue Neoplasm of Uncertain Differentiation approved for …APPROVED_FORderived2 of 2
← approved for	Tazemetostatsmall molecule FDA (US) · approved · 2020-01-23 · Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete res…	—	approved	Epithelioid Sarcoma	1	Regulatory	openfda	graph →
← approved for	Atezolizumab

Soft Tissue Neoplasm of Uncertain Differentiation investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 74show all (up to 200)
→ investigated in trials for	Cyclophosphamidesmall molecule 21 trials (9 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 12 trials (3 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Sirolimussmall molecule 11 trials (2 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 9 trials (6 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Tazemetostatsmall molecule 8 trials (1 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 7 trials (2 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Ifosfamidesmall molecule 7 trials (2 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 7 trials (5 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 7 trials (5 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 6 trials (5 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Pazopanibsmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 5 trials (0 active) · roll-up of the cancer and its descendants	—	—	Soft Tissue Neoplasm of Uncertain Differentiation	5	Observed	clinicaltrials	graph →

Soft Tissue Neoplasm of Uncertain Differentiation investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 74show all (up to 200)

→ investigated in trials for

Cyclophosphamidesmall molecule

21 trials (9 active) · roll-up of the cancer and its descendants

—

Soft Tissue Neoplasm of Uncertain Differentiation

Observed

Soft Tissue Neoplasm of Uncertain Differentiation studied in …STUDIED_INderived10 of 241show all (up to 200)
→ studied in	NCT00001465recruiting Study of the Disease Process of Lymphangioleiomyomatosis · condition mapped ONTOLOGY_EXACT · 241 trials mapped (85 active)	—	—	Lymphangioleiomyomatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07174427Phase 3 · recruiting Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma · condition mapped ONTOLOGY_EXACT · 241 trials mapped (85 active)	—	—	Synovial Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07686367Phase 2 · not yet recruiting Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers · condition mapped CURATED_BROADER · 241 trials mapped (85 active)	—	—	Synovial Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04616560Phase 2 · recruiting Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor · condition mapped ONTOLOGY_EXACT · 241 trials mapped (85 active)	—	—	Desmoplastic Small Round Cell Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05333458Phase 2 · recruiting Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial · condition mapped CURATED_BROADER · 241 trials mapped (85 active)	—	—	Alveolar Soft Part Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06066138Phase 1 · recruiting A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · condition mapped CURATED_BROADER · 241 trials mapped (85 active)	—	—	Alveolar Soft Part Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05252585Phase 4 · active not recruiting A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) · condition mapped ALIAS · 241 trials mapped (85 active)	—	—	Kidney Angiomyolipoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07297667Phase 1 · recruiting GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · condition mapped ONTOLOGY_EXACT · 241 trials mapped (85 active)	—	—	Alveolar Soft Part Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07695311Phase 1 · not yet recruiting EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT · condition mapped ONTOLOGY_EXACT · 241 trials mapped (85 active)	—	—	Desmoplastic Small Round Cell Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT01484236recruiting National Lymphangioleiomyomatosis Registry, France · condition mapped ONTOLOGY_EXACT · 241 trials mapped (85 active)	—	—	Lymphangioleiomyomatosis	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains